Relay Therapeutics(RLAY) - 2024 Q4 - Annual Results

Exhibit 99.1 Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα- mutated, CDK4/6 pre-treated, HR+/HER2- advanced breast cancer Presented interim data for RLY-2608 + fulvestrant showing 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- advanced breast cancer Continued progression of other front-line breast cancer regimens, including i ...